Pharmaceutical Executive-06-01-2022

Click the title above for a link to open the Pharmaceutical Executive June 2022 issue in an interactive PDF format.

The windfall from COVID-19 vaccines and treatments has shaken up Pharm Exec’s latest listing of the top global biopharma sales producers in record-breaking fashion, but a likely leveling off—along with challenging patent and global climates—should shift some of the spotlight to anticipated non-COVID risers and perhaps more definitive maneuvering ahead.

Outlining the implications of this c-suite trend for pharma.

Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.

A flurry of new titles entering the executive ranks has its pros and cons.

Tremeau CEO Bradford Sippy strikes a new chord with revival of old blockbuster drug—modifying it as a unique treatment for orphan hemophilia condition.

Some observations point to hope for an upturn.

How addressing equity gaps can be a boost for brands.

Tips for surviving a shift in executive roles.

Group’s ideas to change EU pricing rules draw captive audience.

Pharma workforce shifting amidst rise of technology in healthcare.

Plan to keep new methods adopted during COVID in place.

As regulatory reform continues to evolve in the US and Europe, the role of regulatory affairs is poised to help shape the more personalized treatment landscape on the horizon.